103127-52-2

Upstream product

• 4732-10-9 (RS)-3-Amino-4-phenyl-1-butene 
• 244092-76-0 (R)-N-(tert-butoxycarbonyl)-3-amino-4-phenyl-1-butene 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 1048990-26-6 C₂₂H₂₇NO₄S 
• 24424-99-5 di-tert-butyl dicarbonate 
• 5619-07-8 methyl 2-amino-3-phenylpropanoate hydrochloride 
• 51987-73-6 methyl 2-tert-butoxycarbonylamino-3-phenylpropanoate 
• 19493-09-5 Methylenetriphenylphosphorane 
• 66605-57-0 (S)-N-tert-butoxycarbonyl-2-amino-3-phenylpropanol 
• 37442-55-0 1-phenylbut-3-en-2-one 
• 63-91-2 L-phenylalanine 
• 2018-61-3 (S)-2-acetylamino-3-phenylpropanoic acid 
• 220035-13-2 (S)-3-acetylamino-4-phenyl-1-butene 

Downstream Products

• 99113-35-6 ((1S,2R)-1-benzyl-2,3-dihydroxypropyl)carbamic acid tert-butyl ester 
• 149451-80-9 (2S,3S)-3-(t-butoxycarbonylamino)-4-phenylbutane-1,2-diol 
• 132259-52-0 (2S,3S)-3--2-hydroxy-4-phenyl-1-(N-prolylisoleucylvaline methyl ester)butane 
• 132234-38-9 (2S,3S)-3-<amino>-2-hydroxy-4-phenyl-1-(N-prolylisoleucinylphenylalanine methyl ester)butane 
• 132234-39-0 (S)-2-((2S,3S)-2-{[(S)-1-((2S,3S)-3-{(S)-3-Carbamoyl-2-[(quinoline-2-carbonyl)-amino]-propionylamino}-2-hydroxy-4-phenyl-butyl)-pyrrolidine-2-carbonyl]-amino}-3-methyl-pentanoylamino)-3-phenyl-propionic acid methyl ester 
• 132234-32-3 (2S,3S)-3-<amino>-2-hydroxy-4-phenyl-1-(N-prolylisoleucylvaline methyl ester)butane 
• 127231-42-9 (2S,3S)-3-<(N-acetylserinylleucinylasparaginyl)amino>-2-hydroxy-4-phenyl-1-(N-prolylisoleucylvaline methyl ester)butane 
• 127231-61-2 (2S,3S)-3-<(N-acetyl-O-benzylserinylleucinylasparaginyl)amino>-2-hydroxy-4-phenyl-1-(N-prolylisoleucylvaline methyl ester)butane 
• 143348-09-8 (2S,3S)-3-<amino>-2-hydroxy-4-phenyl-1-(N-prolylisoleucinylphenylalaninol)butane 
• 857904-14-4 (1S)-1-(2-oxiranyl)-2-phenyl-N-(trifluoromethyl)ethanamine 
• 1310488-87-9 C₁₉H₂₇NO₂ 
• 256950-53-5 (1-benzyl-allyl)-(2-phenyl-allyl)-carbamic acid tert-butyl ester 
• 1310488-75-5 C₁₇H₂₃NO₂ 

Relevant academic research and scientific papers

Reductive one-carbon homologation of aldehydes and ketones

A rhodium-catalyzed methylenation-hydrogenation cascade process allows the homologation of carbonyl compounds to lead to the corresponding alkanes in high yields.

Improved synthesis of chiral N-protected allylic amines

The α-ester group of N-protected α-amino esters was reduced with diisobutylaluminum hydride to an intermediate aluminoxy acetal that on reaction with a Wittig reagent afforded the title chiral compounds in 48-78% chemical yields.

New potential access to ethylenic pseudodipeptides through catalytic alkene metathesis

Dialkenenic amide 1 (R1 = CH2Ph, R2 = H) is readily converted, through ruthenium-catalysed metathetic ring closure, to ethylenic lactam 2, a close precursor of Z-ethylenic pseudodipeptide 3.

Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors

In response to the current pandemic caused by the novel SARS-CoV-2, we design new compounds based on Lopinavir structure as an FDA-approved antiviral agent which is currently under more evaluation in clinical trials for COVID-19 patients. This is the first example of the preparation of Lopinavir isosteres from the main core of Lopinavir conducted to various heterocyclic fragments. It is proposed that main protease inhibitors play an important role in the cycle life of coronavirus. Thus, the protease inhibition effect of synthesized compounds was studied by molecular docking method. All of these 10 molecules, showing a good docking score compared. Molecular dynamics (MD) simulations also confirmed the stability of the best-designed compound in Mpro active site. Communicated by Ramaswamy H. Sarma.

Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D

Following up the open initiative of anti-malarial drug discovery, a GlaxoSmithKline (GSK) phenotypic screening hit was developed to generate hydroxyethylamine based plasmepsin (Plm) inhibitors exhibiting growth inhibition of the malaria parasite Plasmodium falciparum at nanomolar concentrations. Lead optimization studies were performed with the aim of improving Plm inhibition selectivity versus the related human aspartic protease cathepsin D (Cat D). Optimization studies were performed using Plm IV as a readily accessible model protein, the inhibition of which correlates with anti-malarial activity. Guided by sequence alignment of Plms and Cat D, selectivity-inducing structural motifs were modified in the S3 and S4 sub-pocket occupying substituents of the hydroxyethylamine inhibitors. This resulted in potent anti-malarials with an up to 50-fold Plm IV/Cat D selectivity factor. More detailed investigation of the mechanism of action of the selected compounds revealed that they inhibit maturation of the P. falciparum subtilisin-like protease SUB1, and also inhibit parasite egress from erythrocytes. Our results indicate that the anti-malarial activity of the compounds is linked to inhibition of the SUB1 maturase plasmepsin subtype Plm X.

Structure Kinetics Relationships and Molecular Dynamics Show Crucial Role for Heterocycle Leaving Group in Irreversible Diacylglycerol Lipase Inhibitors

Drug discovery programs of covalent irreversible, mechanism-based enzyme inhibitors often focus on optimization of potency as determined by IC50-values in biochemical assays. These assays do not allow the characterization of the binding activity (Ki) and reactivity (kinact) as individual kinetic parameters of the covalent inhibitors. Here, we report the development of a kinetic substrate assay to study the influence of the acidity (pKa) of heterocyclic leaving group of triazole urea derivatives as diacylglycerol lipase (DAGL)-α inhibitors. Surprisingly, we found that the reactivity of the inhibitors did not correlate with the pKa of the leaving group, whereas the position of the nitrogen atoms in the heterocyclic core determined to a large extent the binding activity of the inhibitor. This finding was confirmed and clarified by molecular dynamics simulations on the covalently bound Michaelis-Menten complex. A deeper understanding of the binding properties of covalent serine hydrolase inhibitors is expected to aid in the discovery and development of more selective covalent inhibitors.

A method of preparing intermediates of luck sha neiwei

The invention provides a preparation method for a fosamprenir intermediate. The preparation method comprises the following steps: taking benzyl cyanide as a raw material, and performing steps of nitrile hydrolysis, acylation, reaction with a Grignard reagent, ammonization, cyclizing and the like for synthesizing (2R,3S)-1,2-epoxy-3-t-butyloxycarborylamino-4-phenyl butane. The method is reasonable in process, simple to operate, low in cost and high in yield; with the method, industrialization can be well realized and the production efficiency is improved.

Fluorocyclisation via I(I)/I(III) catalysis: A concise route to fluorinated oxazolines

Herein, we describe a catalytic fluorooxygenation of readily accessible N-allylcarboxamides via an I(I)/I(III) manifold to generate 2-oxazolines containing a fluoromethyl group. Catalysis is conditional on the oxidation competence of Selectfluor, whilst HF serves as both a fluoride source and Br?nsted acid activator. The C(sp3)–F bond of the mono-fluoromethyl unit and the C(sp3)–O bond of the ring are aligned in a synclinal relationship thereby engaging in stabilising hyperconjugative interactions with vicinal, electron-rich σ-bonds (σC–C→σ*C–F and σC–H→σ*C–O). This manifestation of the stereoelectronic gauche effect was established by X-ray crystallographic analysis of a representative example. Given the importance of fluorine in drug discovery, its ability to modulate conformation, and the prevalence of the 2-oxazoline scaffold in Nature, this strategy provides a rapid entry into an important bioisostere class.

Simplified Structural Mimetics of AIPS as Quorum Sensing Inhibitors

Compounds that regulate quorum sensing in Staphylococcal bacteria and in particular in Staphylococcus aureus are provided. Compounds are described in formulas I, II, III, IV, V and VI herein. One or more compounds herein can be employed to inhibit QS and to thus inhibit virulence in Staphylococcus bacteria and in particular in Staphylococcus aureus. Compounds herein and pharmaceutical compositions containing one or more of these compounds are useful, for example, in treating infections of Staphylococcus bacteria and in particular of Staphylococcus aureus. Methods for treating such bacterial infections are provided.

A synthetic zara Wei intermediates (by machine translation)

The invention discloses a method for synthesizing zara Wei intermediate (1S, 2R) - 1 - epoxy ethyl - 2 - phenylethyl amino acid tert-butyl, comprises the following steps: step 1, the 1 - phenyl - 3 - butene - 2 - one in the chiral amino alcohol catalyst 1 under the action of the 2 - nitro-benzylamine generating asymmetric reduction ammoniation reaction, to obtain (S)- 3 - amino - 4 - phenyl - 1 - butene; step 2, will (S)- 3 - amino - 4 - phenyl - 1 - butene with di-T-n-butyl reaction for protecting amino group to obtain (S)- 3 - N - tert-butoxycarbonyl amino - 4 - phenyl - 1 - butene; step 3, will be (S)- 3 - N - tert-butoxycarbonyl amino - 4 - phenyl - 1 - butene in the hand natural spiral alkene phenolalkone iron complex catalyst 2 under the action of the air oxygen in the epoxidation reaction, to obtain (1S, 2R) - 1 - epoxy ethyl - 2 - phenylethyl amino acid tert-butyl. The present invention provides of the important intermediate zara Wei (1S, 2R) - 1 - epoxy ethyl - 2 - phenylethyl amino acid tert-butyl synthetic method of the raw material is cheap, mild reaction conditions, the operation is simple, the synthesis efficiency is high, it is suitable for industrial production, in order to prepare zara Wei and intermediate provides a new way. (by machine translation)